Liquid Biopsy Enables Precision Cancer Care: Bill Morice, M.D., Ph.D.
About this episode
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
During their conversation, Dr. Morice and Dr. Tan explore:
- Inspiration for developing the liquid biopsy.
- Features that differentiate LiquidHALLMARK® from existing cancer tests.
- Patients who will benefit from the test and how an oncologist might use the results.
- The future potential of liquid biopsy advancements.
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Answers from the Lab
Unique Assays Advance Care of Complex Autoimmune Skin Conditions
Answers from the Lab
Digital Advances: What’s Next for Clinical Diagnostics?
Answers from the Lab
Preeclampsia Test Helps Extend Pregnancy to Improve Outcomes
Answers from the Lab
Breakthrough Test Enhances Peripheral Neuropathy Care and Research
Answers from the Lab